Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT01101906 Terminated - Clinical trials for Advanced Hepatocellular Carcinoma (HCC)

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Start date: January 10, 2011
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.

NCT ID: NCT01097083 Terminated - Carcinoma Clinical Trials

Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The hypothesis of this study is that the median time to progression in the experimental arm is 2 months as compared to the placebo arm of 1.4 months

NCT ID: NCT01079767 Terminated - Liver Cancer Clinical Trials

Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis

Start date: January 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well temsirolimus works in treating patients with advanced liver cancer and cirrhosis.

NCT ID: NCT01071434 Terminated - Lung Cancer Clinical Trials

Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors

Start date: February 2009
Phase: N/A
Study type: Observational

This study aims to investigate and optimize imaging sequences and parameters of rapid real-time MRI in order to obtain adequate guidance for accurately and precisely delivering radiation to moving abdominal and thoracic tumors.

NCT ID: NCT01032850 Terminated - Clinical trials for Hepatocellular Carcinoma

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

Start date: September 2009
Phase: Phase 2
Study type: Interventional

This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the following: - how effective this combination of study drugs will be in treating HCC - how long subjects respond to these study drugs - what types of side effects can be expected, and - how severe the side effects are All subjects in this study will receive: - Sorafenib twice a day by mouth - Capecitabine twice a day by mouth Treatment will be given in a 28-day treatment cycle. Subjects will take sorafenib every day of the cycle. Subjects will take capecitabine on days 1-7 and 15-21 of the cycle

NCT ID: NCT01029418 Terminated - Clinical trials for Hepatocellular Carcinoma

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma

Start date: November 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This will be a phase I/II clinical trial testing the combination of sorafenib and AZD6244 in advanced hepatocellular carcinoma with Childs A liver cirrhosis. The aim of the phase I portion is to determine appropriate dose of this drug combination. The phase 2 study will look at effectiveness and safety of this drug combination

NCT ID: NCT01020812 Terminated - Clinical trials for Carcinoma, Hepatocellular

Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma

Start date: September 2009
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the efficacy and toxicity of TACE combined with SBRT

NCT ID: NCT01009801 Terminated - Liver Cancer Clinical Trials

Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

Start date: February 2010
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking the blood flow to the tumor. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether transarterial chemoembolization with doxorubicin is more effective when given alone or when given together with everolimus in treating patients with liver cancer. PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of everolimus when given together with transarterial chemoembolization with doxorubicin and to see how well it works compared with giving transarterial chemoembolization with doxorubicin alone in treating patients with liver cancer.

NCT ID: NCT01009593 Terminated - Neoplasms Clinical Trials

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Start date: January 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.

NCT ID: NCT01005875 Terminated - Clinical trials for Hepatocellular Carcinoma

Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

RAD 0901
Start date: November 2009
Phase: N/A
Study type: Interventional

This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.